MCID: WLL006
MIFTS: 50

Wells Syndrome

Categories: Rare diseases, Skin diseases

Aliases & Classifications for Wells Syndrome

MalaCards integrated aliases for Wells Syndrome:

Name: Wells Syndrome 52 58 71
Eosinophilic Cellulitis 52 58
Bullous Cellulitis with Eosinophilia 52
Wells' Syndrome 52

Characteristics:

Orphanet epidemiological data:

58
wells syndrome
Inheritance: Not applicable; Prevalence: <1/1000000 (Worldwide); Age of onset: Adult; Age of death: normal life expectancy;

Classifications:

Orphanet: 58  
Rare skin diseases


External Ids:

ICD10 32 L98.3
MESH via Orphanet 44 C536693
ICD10 via Orphanet 33 L98.3
UMLS via Orphanet 72 C0343101
Orphanet 58 ORPHA901
UMLS 71 C0343101

Summaries for Wells Syndrome

NIH Rare Diseases : 52 Wells syndrome is a rare eosinophilic disorder that primarily affects the skin. Affected people typically develop a skin rash that is often preceded by itching or burning skin. The rash consists of raised, red, swollen areas that may be warm to the touch. The symptoms generally come on rapidly and may last four to eight weeks. In some cases, the rash may recur (occur frequently or repeatedly) for years. The exact underlying cause of Wells syndrome is currently unknown; however, some scientists believe that it may be an autoimmune reaction . Oral or topical corticosteroids are commonly used to treat Wells syndrome, although antifungal drugs, antibiotics , immunosuppressants , and/or antihistamines have also been used with varying degrees of success.

MalaCards based summary : Wells Syndrome, also known as eosinophilic cellulitis, is related to ankyloblepharon-ectodermal defects-cleft lip/palate and muckle-wells syndrome. An important gene associated with Wells Syndrome is NLRP3 (NLR Family Pyrin Domain Containing 3), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Rilonacept and Antibodies, Monoclonal have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and kidney, and related phenotypes are pruritus and cellulitis

Related Diseases for Wells Syndrome

Diseases related to Wells Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 392)
# Related Disease Score Top Affiliating Genes
1 ankyloblepharon-ectodermal defects-cleft lip/palate 32.7 TP63 SCAF4 HNRNPAB FGFR2
2 muckle-wells syndrome 32.5 TNFRSF1A NLRP3 MEFV IL1RAPL2 IL1R1 IL1B
3 cryopyrin-associated periodic syndrome 32.1 NLRP3 IL1R1 CRP
4 familial cold autoinflammatory syndrome 1 31.3 TNFRSF1A NLRP3 MEFV IL1R1
5 cellulitis 30.6 RNASE3 IL5 IL1R1 CRP
6 urticaria 30.5 RNASE3 NLRP3 IL5 CRP
7 amyloidosis aa 30.3 MEFV CRP
8 onchocerciasis 30.1 RNASE3 IL5 IL2
9 amyloidosis 30.0 TNFRSF1A NLRP3 MEFV CRP
10 cold urticaria 30.0 RNASE3 NLRP3 IL1RAPL2 IL1R1
11 papilledema 29.9 NLRP3 IL1R1 CRP
12 arthropathy 29.9 NLRP3 IL1RAPL2 IL1B CRP
13 churg-strauss syndrome 29.9 RNASE3 IL5 IL2 CXCL8
14 conjunctivitis 29.8 RNASE3 NLRP3 IL5 IL2 CXCL8
15 hypereosinophilic syndrome 29.8 RNASE3 IL5 IL2RA IL2 CXCL8
16 exanthem 29.8 NLRP3 MEFV IL2 CXCL8 CRP
17 dermatitis 29.7 RNASE3 IL5 IL2 CXCL8
18 aseptic meningitis 29.6 NLRP3 IL1R1 IL1B CXCL8
19 familial cold autoinflammatory syndrome 29.6 NLRP3 MEFV IL1RAPL2 IL1R1 IL1B
20 hereditary periodic fever syndrome 29.6 TNFRSF1A NLRP3 MEFV
21 erysipelas 29.5 MEFV IL2 CRP
22 toxocariasis 29.5 RNASE3 IL5 CRP
23 ascaris lumbricoides infection 29.5 IL5 IL1B CXCL8
24 allergic hypersensitivity disease 29.5 RNASE3 IL5 IL2 CXCL8
25 eosinophilic pneumonia 29.5 RNASE3 IL5 CXCL8
26 contact dermatitis 29.5 IL5 IL2 IL1B CXCL8
27 end stage renal failure 29.4 IL2RA IL2 IL1R1 CRP
28 colitis 29.2 IL2 IL1R1 IL1B CXCL8
29 diphtheria 29.2 IL5 IL2RA IL2
30 ulcerative colitis 29.1 IL2 IL1R1 IL1B CXCL8 CRP
31 synovitis 29.1 TNFRSF1A IL1B CXCL8 CRP
32 relapsing fever 29.1 TNFRSF1A MEFV CRP
33 tetanus 29.1 IL5 IL2RA IL2 IL1B CRP
34 rubella 29.1 IL5 IL2RA IL2
35 chronic meningitis 29.0 NLRP3 MEFV IL5 CRP
36 otitis media 28.9 RNASE3 IL5 IL1B CXCL8 CRP
37 pharyngitis 28.9 NLRP3 MEFV IL1B CXCL8 CRP
38 mumps 28.8 TNFRSF1A IL2RA IL2 CXCL8
39 uveitis 28.8 TNFRSF1A IL2RA IL2 IL1R1 CXCL8
40 celiac disease 1 28.6 IL5 IL2RA IL2 CXCL8 CRP
41 pericarditis 28.6 TNFRSF1A MEFV IL1B CXCL8 CRP
42 pneumonia 28.6 NLRP3 IL5 IL2 IL1B CXCL8 CRP
43 cinca syndrome 28.5 TNFRSF1A NLRP3 MEFV IL1RAPL2 IL1R1 IL1B
44 skin disease 28.5 TP63 RNASE3 IL5 IL2 CXCL8 CRP
45 bone inflammation disease 28.5 TNFRSF1A NLRP3 IL2 IL1B CXCL8 CRP
46 rheumatic disease 28.4 MEFV IL2RA IL1RAPL2 IL1R1 IL1B CRP
47 dermatitis, atopic 28.3 RNASE3 IL5 IL2RA IL2 IL1B CXCL8
48 familial mediterranean fever 28.3 TNFRSF1A NLRP3 MEFV IL1R1 IL1B CRP
49 asthma 27.7 RNASE3 NLRP3 IL5 IL2RA IL2 IL1R1
50 proteasome-associated autoinflammatory syndrome 1 27.7 RNASE3 NLRP3 MEFV IL5 IL1RAPL2 IL1R1

Graphical network of the top 20 diseases related to Wells Syndrome:



Diseases related to Wells Syndrome

Symptoms & Phenotypes for Wells Syndrome

Human phenotypes related to Wells Syndrome:

58 31 (show all 9)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pruritus 58 31 hallmark (90%) Very frequent (99-80%) HP:0000989
2 cellulitis 58 31 hallmark (90%) Very frequent (99-80%) HP:0100658
3 abnormal blistering of the skin 58 31 frequent (33%) Frequent (79-30%) HP:0008066
4 edema 58 31 frequent (33%) Frequent (79-30%) HP:0000969
5 skin vesicle 58 31 frequent (33%) Frequent (79-30%) HP:0200037
6 eosinophilia 58 31 frequent (33%) Frequent (79-30%) HP:0001880
7 fever 58 31 occasional (7.5%) Occasional (29-5%) HP:0001945
8 arthralgia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002829
9 vasculitis 58 Excluded (0%)

GenomeRNAi Phenotypes related to Wells Syndrome according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.72 CXCL8 IL1B IL2 IL2RA NLRP3 TNFRSF1A
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.72 CXCL8 IL1B IL2 IL2RA NLRP3 TNFRSF1A

MGI Mouse Phenotypes related to Wells Syndrome:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.18 FGFR2 HNRNPAB IL1B IL1R1 IL2 IL2RA
2 homeostasis/metabolism MP:0005376 10.18 CRP FGFR2 HNRNPAB IL1B IL1R1 IL2
3 immune system MP:0005387 10.06 CRP FGFR2 IL1B IL1R1 IL2 IL2RA
4 digestive/alimentary MP:0005381 9.98 FGFR2 IL2 IL2RA IL5 NLRP3 TNFRSF1A
5 integument MP:0010771 9.86 FGFR2 IL1B IL1R1 MEFV NLRP3 RACK1
6 liver/biliary system MP:0005370 9.7 FGFR2 IL1R1 IL2 IL5 MEFV NLRP3
7 neoplasm MP:0002006 9.5 FGFR2 IL1B IL1R1 IL2 IL5 TNFRSF1A
8 respiratory system MP:0005388 9.17 FGFR2 IL1R1 IL2 IL2RA IL5 TNFRSF1A

Drugs & Therapeutics for Wells Syndrome

Drugs for Wells Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 9)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rilonacept Approved, Investigational Phase 3 501081-76-1 104924
2 Antibodies, Monoclonal Phase 3
3 Immunoglobulins Phase 3
4 Antibodies Phase 3
5 Immunologic Factors Phase 3
6 Anti-Inflammatory Agents Phase 3
7 Vaccines Phase 3
8 Antirheumatic Agents Phase 1, Phase 2
9 Interleukin 1 Receptor Antagonist Protein Phase 2

Interventional clinical trials:

(show all 18)
# Name Status NCT ID Phase Drugs
1 A Three-part,Multicenter Study,With a Randomized,Double-blind,Placebo Controlled,Withdrawal Design in Part II to Assess Efficacy,Safety,and Tolerability of ACZ885(Anti-interleukin-1beta Monoclonal Antibody)in Patients With Muckle-Wells Syndrome Completed NCT00465985 Phase 3 ACZ885;Placebo
2 An Open-label, Efficacy and Safety Study of Canakinumab (Anti-interleukin-1β Monoclonal Antibody) Administered for 6 Months (24 Weeks) in Japanese Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease, Followed by an Extension Phase to Provide Canakinumab to Study Patients Until it is Approved and Marketed in Japan Completed NCT00991146 Phase 3 canakinumab
3 An Open-label, Long-term Safety and Efficacy Study of ACZ885 (Anti-interleukin-1β Monoclonal Antibody) Administered for at Least 6 Months in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease Completed NCT00685373 Phase 3 Canakinumab (ACZ885)
4 An Open-label Extension Study to Assess Efficacy, Safety and Tolerability of Canakinumab and the Efficacy and Safety of Childhood Vaccinations in Patients With Cryopyrin Associated Periodic Syndromes (CAPS) Completed NCT01576367 Phase 3
5 An Open Label Study to Assess the Safety, Tolerability and Efficacy of Canakinumab (ACZ885) in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada Completed NCT01105507 Phase 3 canakinumab (company code: ACZ885D)
6 A One-year Open-label, Multicenter Trial to Assess Efficacy, Safety and Tolerability of Canakinumab (ACZ885) and the Efficacy and Safety of Childhood Vaccinations in Patients Aged 4 Years or Younger With Cryopyrin Associated Periodic Syndromes (CAPS) Completed NCT01302860 Phase 3 ACZ885
7 A French Open-label Extension Study of Canakinumab in Patients Who Participated in International Phase III Studies CACZ885G2301E1 or CACZ885G2306 in Systemic Juvenile Idiopathic Arthritis and CACZ885N2301 in Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF) Completed NCT02334748 Phase 3 canakinumab
8 IL1T-AI-0505: A Multi-center, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, & Efficacy of Rilonacept in Subjects With Cryopyrin-Associated Periodic Syndromes (CAPS) Using Parallel Group & Randomized Withdrawal Designs Completed NCT00288704 Phase 3 rilonacept 160 mg;Placebo;rilonacept 160 mg
9 A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany With Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome (CAPS), or Schnitzler Syndrome (SchS) Completed NCT01045772 Phase 2 rilonacept
10 An Open-Label, Phase II Dose Titration Study of ACZ885 (Human Anti-IL-1β Monoclonal Antibody) to Assess the Clinical Efficacy, Safety, Pharmacokinetics and Pharmacodynamics in Patients With NALP3 Mutations Completed NCT00487708 Phase 2 canakinumab
11 Continuation of a Pilot Open-Label Study of IL 1 Trap in Adult Subjects With Autoinflammatory Diseases: A Therapeutic Approach to Study Pathogenesis Completed NCT00094900 Phase 2 IL-1 Trap
12 A Pilot Study of Anakinra in Behcet's Disease (BD) Completed NCT01441076 Phase 1, Phase 2 Anakinra
13 A Pilot Open-Label Study of Rilonacept (Arcalyst) in the Deficiency of the Interleukin-1 Receptor Antagonist (DIRA) Completed NCT01801449 Phase 2 Rilonacept
14 An Open Label, Single Arm Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of HL2351 in Patients With Cryopyrin Associated Periodic Syndromes Terminated NCT02853084 Phase 2 HL2351
15 A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome (FCAS) / Muckle-Wells Syndrome (MWS) and Behcet's Disease (BD) Withdrawn NCT01211977 Phase 1, Phase 2 XOMA 052
16 An Open-label, Long-term, Prospective, Observational Study to Monitor the Safety and Effectiveness of Ilaris in CAPS Patients Completed NCT01213641
17 Schnitzler Syndrome: Clinical Study, Physiopathological and Search for Genetic Completed NCT00933296
18 Genetics and Pathophysiology of Autoinflammatory Disorders. Recruiting NCT00001373

Search NIH Clinical Center for Wells Syndrome

Genetic Tests for Wells Syndrome

Anatomical Context for Wells Syndrome

MalaCards organs/tissues related to Wells Syndrome:

40
Skin, Lung, Kidney, Monocytes, T Cells, Eye, Thyroid

Publications for Wells Syndrome

Articles related to Wells Syndrome:

(show top 50) (show all 596)
# Title Authors PMID Year
1
Wells syndrome (eosinophilic cellulitis) following vaccination: two pediatric cases withpositive patch test to aluminium salts. 61
32034766 2020
2
Wells syndrome after radiation therapy. 61
31960465 2020
3
[SYSTEMIC REVIEW OF EOSINOPHILIC DERMATOSES PATIENTS TREATED WITH TNF-Α INHIBITORS AND USTEKINUMAB]. 61
31930806 2020
4
Erysipelas-like presentation of Wells' syndrome (eosinophilic cellulitis). 61
31995962 2020
5
Ocular Involvement in Muckle-Wells Syndrome. 61
30556770 2020
6
Erratum: Muckle-Wells syndrome in an Indian family associated with NLRP3 mutation. 61
31929316 2020
7
The Long-Term Efficacy of Cochlear Implantation for Hearing Loss in Muckel-Wells Syndrome. 61
31846928 2019
8
Cryopyrin-associated periodic fever syndrome in children: A case-based review. 61
31858722 2019
9
Wells' syndrome associated with Trichophyton infection. 61
31502286 2019
10
Rapid and Sustained Long-Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin-Associated Periodic Syndrome Ages Five Years and Younger. 61
31161734 2019
11
Eosinophilic dermatoses. 61
31562692 2019
12
Wells syndrome and chronic spontaneous urticaria: report of four cases successfully treated with omalizumab. 61
31106467 2019
13
Recognising and understanding cryopyrin-associated periodic syndrome in adults. 61
31597069 2019
14
Periodic fever: From Still's disease to Muckle-Wells syndrome. 61
28583784 2019
15
The color of skin: green diseases of the skin, nails, and mucosa. 61
31896406 2019
16
Long-term remission of Wells syndrome with omalizumab. 61
31530507 2019
17
Wells Syndrome - An Odyssey. 61
31850109 2019
18
Erythema Nodosum, Early Stage-A Subcutaneous Variant of Leukocytoclastic Vasculitis? Clinicopathological Correlation in a Series of 13 Patients. 61
31436577 2019
19
Wells' syndrome: the importance of differential diagnosis. 61
31365676 2019
20
Bullous Wells Syndrome. 61
31431235 2019
21
Eosinophilic Cellulitis Successfully Treated with Colchicine. 61
31334073 2019
22
Insect bites as a trigger factor of eosinophilic cellulitis. 61
31232056 2019
23
The NLRP3 p.A441V Mutation in NLRP3-AID Pathogenesis: Functional Consequences, Phenotype-Genotype Correlations and Evidence for a Recurrent Mutational Event. 61
31777803 2019
24
Spectrum of the neurologic manifestations in childhood-onset cryopyrin-associated periodic syndrome. 61
30967326 2019
25
Diagnostic utility of a targeted next-generation sequencing gene panel in the clinical suspicion of systemic autoinflammatory diseases: a multi-center study. 61
30783801 2019
26
Is chemotherapy the best option for chronic lymphocytic leukemia associated Wells' syndrome? Reply to "Case of Wells' syndrome: A rare association with the clinical course of chronic lymphocytic leukemia". 61
30362593 2019
27
Early canakinumab therapy for the sensorineural deafness in a family with Muckle-Wells syndrome due to a novel mutation of NLRP3 gene. 61
30338413 2019
28
Case of Wells' syndrome: A rare association with the clinical course of chronic lymphocytic leukemia. 61
30063068 2019
29
The NLRP3 inflammasome: a new player in neurological diseases. 61
31892810 2019
30
INTERMEDIATE UVEITIS ASSOCIATED WITH PERIODIC FEVER, APHTHOUS STOMATITIS, PHARYNGITIS, AND CERVICAL ADENITIS SYNDROME. 61
28570435 2019
31
Muckle-Wells Syndrome Across Four Generations in One Czech Family: Natural Course of the Disease. 61
31057541 2019
32
Wells' Syndrome Induced by Ustekinumab. 61
30685913 2019
33
[Renal amyloidosis revealing a cryopyrin associated periodic syndrome]. 61
30236822 2018
34
Centipede envenomation: Clinical importance and the underlying molecular mechanisms. 61
30273703 2018
35
Wells' syndrome associated with eosinophilic panniculitis presenting with multiple subcutaneous nodules. 61
30325316 2018
36
A Case of Muckle-Wells Syndrome due to novel NLRP3 mutation. 61
30157308 2018
37
Prolonged Treatment of Eosinophilic Erythema Annulare with Chloroquine. 61
30390730 2018
38
De novo ATP1A3 and compound heterozygous NLRP3 mutations in a child with autism spectrum disorder, episodic fatigue and somnolence, and muckle-wells syndrome. 61
29922587 2018
39
Pediatric Wells syndrome (eosinophilic cellulitis) after vaccination: A case report and review of the literature. 61
29998475 2018
40
Wells syndrome in a patient receiving adalimumab biosimilar: A case report and review of literature. 61
30058563 2018
41
Wells syndrome: a case of successful treatment with omalizumab. 61
29707773 2018
42
Wells' Syndrome Associated with Coxsackievirus A6 Infection. 61
29972218 2018
43
C3 glomerulopathy in NLRP12-related autoinflammatory disorder: case-based review. 61
29951964 2018
44
A Case of Amyloidosis Caused by Sporadic Muckle-Wells Syndrome: Response to Treatment With Anakinra. 61
29239931 2018
45
The Future of IL-1 Targeting in Kidney Disease. 61
29968152 2018
46
Expanding the genetic profile of Hay-Wells syndrome. 61
29329681 2018
47
Eosinophilic cellulitis (Wells syndrome) successfully treated with mepolizumab. 61
29892672 2018
48
Wells syndrome (eosinophilic cellulitis) caused by adrenal insufficiency and relieved by cortisone supplementation. 61
29398098 2018
49
Wells' syndrome-like reaction following Argas reflexus bites. 61
29400289 2018
50
Wells syndrome secondary to influenza vaccination: A case report and review of the literature. 61
29240526 2018

Variations for Wells Syndrome

Expression for Wells Syndrome

Search GEO for disease gene expression data for Wells Syndrome.

Pathways for Wells Syndrome

Pathways related to Wells Syndrome according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.91 TNFRSF1A RNASE3 NLRP3 MEFV IL5 IL2RA
2
Show member pathways
13.76 TNFRSF1A RACK1 IL5 IL2RA IL2 IL1R1
3
Show member pathways
13.62 TNFRSF1A IL5 IL2RA IL2 IL1R1 IL1B
4
Show member pathways
13.49 TNFRSF1A IL5 IL2RA IL2 IL1R1 IL1B
5
Show member pathways
13.36 TNFRSF1A IL5 IL2RA IL2 IL1R1 IL1B
6
Show member pathways
13.3 TNFRSF1A IL5 IL2RA IL2 IL1R1 IL1B
7
Show member pathways
13.18 TNFRSF1A IL5 IL2RA IL2 IL1R1 IL1B
8 12.79 IL5 IL2RA IL2 FGFR2 CXCL8
9
Show member pathways
12.79 RNASE3 IL5 IL2RA IL2 IL1B CXCL8
10
Show member pathways
12.66 TNFRSF1A IL2 IL1R1 IL1B FGFR2
11
Show member pathways
12.62 TNFRSF1A RACK1 NLRP3 IL2RA IL2 IL1B
12
Show member pathways
12.55 IL5 IL2RA IL2 IL1R1 IL1B
13 12.5 TNFRSF1A IL2RA IL2 IL1B
14 12.3 TNFRSF1A IL2RA IL2 IL1R1
15
Show member pathways
12.29 TNFRSF1A IL2RA IL2 CXCL8
16 12.29 TNFRSF1A NLRP3 IL1R1 IL1B CXCL8
17 12.19 NLRP3 MEFV IL1B CXCL8
18 12.18 TNFRSF1A NLRP3 IL1R1 IL1B CXCL8
19
Show member pathways
12.16 IL5 IL2RA IL2 IL1R1 IL1B FGFR2
20
Show member pathways
12.12 IL5 IL2RA IL2 IL1B FGFR2 CXCL8
21 11.99 IL2 IL1R1 IL1B CXCL8
22
Show member pathways
11.95 IL2RA IL2 IL1R1 IL1B
23 11.87 IL1R1 IL1B CXCL8
24 11.87 TNFRSF1A IL1R1 IL1B CXCL8
25 11.84 IL5 IL2RA IL1R1 IL1B
26
Show member pathways
11.81 IL5 IL2RA IL2 IL1R1 IL1B
27 11.76 IL5 IL2 CXCL8
28 11.72 NLRP3 IL1B CXCL8
29
Show member pathways
11.68 IL5 IL2RA IL2 CXCL8
30 11.63 IL5 IL1B CXCL8
31 11.63 NLRP3 MEFV IL2 IL1B CXCL8
32
Show member pathways
11.56 TNFRSF1A IL2 IL1B CXCL8
33 11.47 IL5 IL2RA IL2
34 11.41 NLRP3 MEFV IL1B
35 11.4 TNFRSF1A IL1R1 IL1B CXCL8
36 11.24 IL5 IL2 IL1B
37
Show member pathways
11.17 IL2RA IL2 HNRNPAB
38 11.14 NLRP3 IL1R1 IL1B
39 10.97 IL5 IL2 IL1B FGFR2 CXCL8
40 10.92 IL5 IL2RA IL2 IL1R1 IL1B
41 10.78 TNFRSF1A IL5 IL2RA IL2

GO Terms for Wells Syndrome

Cellular components related to Wells Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.32 TNFRSF1A RNASE3 NLRP3 IL5 IL2 IL1R1

Biological processes related to Wells Syndrome according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.85 IL5 IL2RA IL2 IL1R1 IL1B CXCL8
2 apoptotic process GO:0006915 9.8 TP63 TNFRSF1A RACK1 NLRP3 IL2RA IL1B
3 defense response to Gram-positive bacterium GO:0050830 9.76 RNASE3 NLRP3 CRP
4 positive regulation of inflammatory response GO:0050729 9.74 TNFRSF1A IL2 IL1B
5 MAPK cascade GO:0000165 9.72 IL5 IL2RA IL2 IL1B FGFR2
6 positive regulation of T cell proliferation GO:0042102 9.7 IL2RA IL2 IL1B
7 positive regulation of interferon-gamma production GO:0032729 9.63 IL2 IL1R1 IL1B
8 regulation of regulatory T cell differentiation GO:0045589 9.59 IL2RA IL2
9 positive regulation of immunoglobulin secretion GO:0051024 9.58 IL5 IL2
10 positive regulation of ceramide biosynthetic process GO:2000304 9.56 TNFRSF1A RACK1
11 inflammatory response GO:0006954 9.56 TNFRSF1A NLRP3 MEFV IL5 IL1R1 IL1B
12 interleukin-2-mediated signaling pathway GO:0038110 9.55 IL2RA IL2
13 negative regulation of inflammatory response GO:0050728 9.55 TNFRSF1A NLRP3 MEFV IL2RA IL2
14 regulation of establishment of endothelial barrier GO:1903140 9.54 TNFRSF1A IL1B
15 negative regulation of lymphocyte proliferation GO:0050672 9.51 IL2RA IL2
16 positive regulation of T-helper 1 cell cytokine production GO:2000556 9.49 IL1R1 IL1B
17 interleukin-1 beta production GO:0032611 9.48 NLRP3 IL1B
18 regulation of T cell homeostatic proliferation GO:0046013 9.43 IL2RA IL2
19 squamous basal epithelial stem cell differentiation involved in prostate gland acinus development GO:0060529 9.4 TP63 FGFR2
20 cytokine-mediated signaling pathway GO:0019221 9.23 TNFRSF1A IL5 IL2RA IL2 IL1RAPL2 IL1R1

Molecular functions related to Wells Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 IL5 IL2 IL1B CXCL8
2 interleukin-1 receptor activity GO:0004908 8.62 IL1RAPL2 IL1R1

Sources for Wells Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....